KIORA PHARMACEUTICALS, INC. Business Combination, Contingent Consideration, Liability
KIORA PHARMACEUTICALS, INC. (KPRX) had Business Combination, Contingent Consideration, Liability of $16.64 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Liabilities
us-gaap:BusinessCombinationContingentConsiderationLiability · last filed 2026-08-07
- 2026-06-30: Business Combination, Contingent Consideration, Liability $16.64M.
- 2026-03-31: Business Combination, Contingent Consideration, Liability $16.64M.
- 2025-09-30: Business Combination, Contingent Consideration, Liability $16.64M.
- 2025-06-30: Business Combination, Contingent Consideration, Liability $16.64M.
| Period end | Business Combination, Contingent Consideration, Liability |
|---|---|
| 2026-06-30 | $16.64M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $16.64M 10-Q · filed 2026-05-08 |
| 2025-09-30 | $16.64M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $16.64M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $16.64M 10-Q · filed 2025-05-09 |
| 2024-09-30 | $16.64M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $18.80M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $18.80M 10-Q · filed 2024-05-10 |
| 2023-09-30 | $18.80M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $18.80M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $18.80M 10-Q · filed 2023-05-09 |
| 2022-09-30 | $18.80M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $18.80M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $18.80M 10-Q · filed 2022-07-08 |
| 2021-12-31 | $0.00 10-K · filed 2022-04-15 |
| 2020-12-31 | $0.00 10-K · filed 2022-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |